Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.4
26.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co Ltd
Income to Minority Interest
Henan Lingrui Pharmaceutical Co Ltd
Income to Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income to Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
|
Income to Minority Interest
-¥37.3k
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income to Minority Interest
-¥25.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income to Minority Interest
¥5.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income to Minority Interest
-¥32.7m
|
CAGR 3-Years
-228%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Henan Lingrui Pharmaceutical Co Ltd
Glance View
Nestled in the heart of China's Henan province, Henan Lingrui Pharmaceutical Co Ltd has quietly crafted a legacy in the pharmaceutical sector, blending traditional Chinese medicine with modern medical practices. Founded in an environment rich in natural resources, the company takes pride in its extensive portfolio that includes a broad range of pharmaceutical products such as tablets, injections, ointments, and Chinese patent medicines. The company's approach is an intricate dance between ancient wisdom and contemporary science, where herbal remedies are often synthesized with cutting-edge pharmaceutical manufacturing processes. Priding itself on research and development, Lingrui regularly collaborates with esteemed medical institutions, ensuring that its offerings remain both innovative and deeply rooted in traditional therapeutic principles. The financial heartbeat of Henan Lingrui is sustained through a strategic balance of domestic sales and international exports, capitalizing on the rising global demand for natural and alternative medicines. As the company expands its footprint, it continues to harness its robust supply chain and distribution channels to seamlessly deliver its products to hospitals, pharmacies, and health institutions across various regions. Indeed, the harmonious blend of traditional and modern methodologies not only defines Lingrui's operations but also shapes its revenue streams. By adhering to stringent quality standards and fostering partnerships, Henan Lingrui Pharmaceutical not only thrives in its local market but also competes in diverse international arenas, leveraging its unique product offerings as a cornerstone for financial growth.
See Also
What is Henan Lingrui Pharmaceutical Co Ltd's Income to Minority Interest?
Income to Minority Interest
-37.3k
CNY
Based on the financial report for Sep 30, 2024, Henan Lingrui Pharmaceutical Co Ltd's Income to Minority Interest amounts to -37.3k CNY.
What is Henan Lingrui Pharmaceutical Co Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 10Y
19%
The average annual Income to Minority Interest growth rates for Henan Lingrui Pharmaceutical Co Ltd have been 67% over the past three years , and 19% over the past ten years .
You don't have any saved screeners yet
